What are the current treatment guidelines for urinary tract infection in adults, including uncomplicated and complicated cases?

Latest UTI Treatment Guidelines (2024)

For uncomplicated cystitis in women, use fosfomycin trometamol 3g single dose, nitrofurantoin 100mg twice daily for 5 days, or pivmecillinam 400mg three times daily for 3-5 days as first-line therapy, avoiding fluoroquinolones and cephalosporins to minimize collateral damage and resistance development. 1

Uncomplicated Cystitis (Lower UTI in Women)

Diagnosis

• Clinical diagnosis based on dysuria, frequency, urgency, and absence of vaginal discharge is sufficient 1
• Urine culture is NOT needed for typical presentations 1
• Order urine culture only if: suspected pyelonephritis, symptoms persist/recur within 4 weeks, atypical symptoms, or pregnancy 1

Treatment Options

First-line agents (women):

• Fosfomycin trometamol: 3g single dose 1
• Nitrofurantoin: 100mg twice daily × 5 days 1
• Pivmecillinam: 400mg three times daily × 3-5 days 1

Alternative agents (use only if local E. coli resistance <20%):

• Cephalosporins (e.g., cefadroxil 500mg twice daily × 3 days) 1
• Trimethoprim: 200mg twice daily × 5 days 1
• Trimethoprim-sulfamethoxazole: 160/800mg twice daily × 3 days 1

Treatment in men:

• Trimethoprim-sulfamethoxazole: 160/800mg twice daily × 7 days 1
• Fluoroquinolones may be used based on local susceptibility 1

Important Caveats

• Symptomatic therapy alone (ibuprofen) may be considered for mild-moderate symptoms in women who prefer to avoid antibiotics after discussing risks/benefits 1
• Fluoroquinolones and cephalosporins are NOT first-line due to unfavorable microbiome impact and resistance concerns 1

Uncomplicated Pyelonephritis (Upper UTI)

Outpatient Oral Therapy

Fluoroquinolones (only if local resistance <10%):

• Ciprofloxacin: 500-750mg twice daily × 7 days 1
• Levofloxacin: 750mg daily × 5 days 1

Oral cephalosporins (give initial IV ceftriaxone dose first):

• Cefpodoxime: 200mg twice daily × 10 days 1
• Ceftibuten: 400mg daily × 10 days 1

Alternative:

• Trimethoprim-sulfamethoxazole: 160/800mg twice daily × 14 days 1

Critical point: Nitrofurantoin, fosfomycin, and pivmecillinam should be AVOIDED for pyelonephritis due to insufficient efficacy data 1

Hospitalized Patients - IV Therapy

First-line IV options:

• Ciprofloxacin: 400mg twice daily 1
• Levofloxacin: 750mg daily 1
• Ceftriaxone: 1-2g daily (higher dose recommended) 1
• Cefepime: 1-2g twice daily 1
• Gentamicin: 5mg/kg daily (with or without ampicillin) 1
• Piperacillin/tazobactam: 2.5-4.5g three times daily 1

Reserve carbapenems and novel agents (meropenem, ceftolozane/tazobactam, ceftazidime/avibactam) ONLY for early culture results showing multidrug-resistant organisms 1

Key Clinical Decision Point

Imaging is crucial: Obtain imaging after 72 hours if fever persists or immediately if clinical deterioration occurs to rule out obstruction, as obstructive pyelonephritis can rapidly progress to urosepsis 1

Complicated UTI (cUTI)

Defining Features

Complicated UTI occurs with any of these factors 1:

• Urinary obstruction at any site
• Foreign body/catheter
• Male sex
• Pregnancy
• Diabetes mellitus
• Immunosuppression
• Recent instrumentation
• Healthcare-associated infection
• ESBL or multidrug-resistant organisms

Management Principles

1. Always obtain urine culture and susceptibility testing 1
2. Address underlying urological abnormality - this is mandatory 1
3. Broader microbial spectrum expected: E. coli, Proteus, Klebsiella, Pseudomonas, Serratia, Enterococcus 1

Treatment Duration

• 7-14 days depending on clinical response and underlying abnormality 1
• 14 days for men when prostatitis cannot be excluded 1, 2
• May shorten to 7 days if hemodynamically stable and afebrile ≥48 hours 1
• Recent 2025 IDSA guidelines suggest 5-7 days of fluoroquinolone or 7 days of non-fluoroquinolone for improving patients, regardless of bacteremia presence 2

Recurrent UTI (rUTI)

Definition

≥3 UTIs per year OR ≥2 UTIs in last 6 months 1

Diagnostic Approach

• Always confirm with urine culture 1
• Do NOT perform extensive workup (cystoscopy, full abdominal ultrasound) in women <40 years without risk factors 1

Prevention Strategies

Prioritize non-antibiotic prophylaxis first 1:

• Increase fluid intake in premenopausal women 1
• Consider vaginal estrogen in postmenopausal women
• Behavioral modifications

Note: Evidence for probiotics and D-mannose remains insufficient for clear recommendations 3

Asymptomatic Bacteriuria (ABU)

Do NOT Screen or Treat in:

• Women without risk factors 1
• Well-controlled diabetes 1
• Postmenopausal women 1
• Elderly institutionalized patients 1
• Dysfunctional/reconstructed lower urinary tract 1
• Renal transplant patients 1
• Before arthroplasty surgery 1
• Patients with recurrent UTIs 1

DO Screen and Treat:

• Before urological procedures breaching mucosa (strong recommendation) 1
• Pregnant women (use standard short-course or single-dose fosfomycin) 1

Critical Pitfalls to Avoid

1. Do not use nitrofurantoin, fosfomycin, or pivmecillinam for pyelonephritis - insufficient tissue penetration 1

2. Fluoroquinolone resistance must be <10% before using empirically for pyelonephritis 1

3. Do not routinely culture uncomplicated cystitis - overdiagnosis leads to unnecessary treatment 1

4. Shorter antibiotic courses for pyelonephritis increase recurrence risk within 4-6 weeks - tailor to local patterns 1

5. Reserve carbapenems strictly for documented multidrug-resistant organisms to preserve efficacy 1

6. Men with febrile UTI may have occult prostatitis - consider 10-14 day courses 2

These 2024 European Association of Urology guidelines emphasize antibiotic stewardship through narrow-spectrum agents, shorter durations when appropriate, and avoiding unnecessary testing while maintaining clinical effectiveness.